L. E. Abrey - Concepedia

Author

L. E. Abrey

Memorial Sloan Kettering Cancer Center

Also Known As

F. G. Kamar, L. E. Abrey, Lauren E. Abrey, R. M. Green, R. Mott

Publications

679

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Harvard University Press University of California, Los Angeles University of Virginia

About

L. E. Abrey is an author at Memorial Sloan Kettering Cancer Center specializing in cancer therapeutics, glioma, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	419
2	Neurology	3	3	419
3	Pharmacology	3	3	419
4	Cancer Therapeutics	3	3	419
5	Health Sciences	1	1	105

L. E. Abrey

Publications

674

Citations

H-Index

Page 1

	Year	Citations
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Jeffery J. Raizer, L. E. Abrey, Andrew B. Lassman, Neuro-Oncology PharmacotherapyHigh-grade GliomasGliomaNeuro-oncologyOncology	2009	294
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas Raja B. Khan, Jeffrey J. Raizer, Mark G. Malkin, Neuro-Oncology Standard DosagePhase Ii StudyPharmacotherapyHigh-grade GliomasGlioma	2002	105
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab J.S. Wefel, Timothy F. Cloughesy, James L. Zazzali, Neuro-Oncology	2011	104
Initial treatment patterns over time for anaplastic oligodendroglial tumors Katherine S. Panageas, Fábio M. Iwamoto, Timothy F. Cloughesy, Neuro-Oncology	2012	56
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas Jeffrey J. Raizer, L. E. Abrey, Andrew B. Lassman, Neuro-Oncology	2009	53
High Dose Chemotherapy with Autologous Stem Cell Rescue in Adults with Malignant Primary Brain Tumors L. E. Abrey, Marc K. Rosenblum, Esperanza B. Papadopoulos, Journal of Neuro-Oncology	1999	28
Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05–02) Patrick Y. Wen, T. Cloughesy, J. Kuhn, Journal of Clinical Oncology Phase I/ii StudyPharmacotherapyHigh-grade GliomasRecurrent GlioblastomaGlioma	2009	20
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors Katherine S. Panageas, Anne S. Reiner, Fábio M. Iwamoto, Neuro-Oncology	2014	14

Page 1